Press Releases Check out the latest news from Tavanta May 31, 2023 Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses May 24, 2023 Tavanta Therapeutics Announces New Preclinical Data for its Cystic Fibrosis Candidate TAVT-135 at Two Prominent Scientific Conferences January 05, 2023 Tavanta Therapeutics Announces Positive Top-line Results from Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer October 28, 2022 Tavanta Therapeutics to Present Preclinical Data for TAVT-135 at the North American Cystic Fibrosis Conference August 01, 2022 Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer July 12, 2021 Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer August 31, 2020 Tavanta Therapeutics, a New Specialty Pharmaceutical Company, Has Diverse Pipeline of Novel Drugs and Risk-balanced Approach to Product Development October 29, 2019 DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT-45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer October 21, 2019 Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and New President of DRGT Research September 18, 2019 DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99) July 15, 2019 DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure June 10, 2019 DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor February 05, 2019 DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development December 06, 2018 Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer May 02, 2018 Best in Class Erectile Dysfunction Drug – DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99 October 05, 2017 DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform December 19, 2016 DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market December 14, 2016 Dr. Philip Kantoff – leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor December 09, 2016 DRGT’s novel Abiraterone Acetate composition provides opportunity for dose reduction and increased efficacy in prostate cancer June 23, 2015 Quotient Clinical Begins Prostate Cancer Project for Druggability Technologies December 05, 2013 Druggability Technologies enters into a strategic collaboration with Bayer HealthCare
